Elsevier

HPB

Volume 17, Issue 5, May 2015, Pages 409-415
HPB

Original Articles
A qualitative study of patient and clinician attitudes regarding surveillance after a resection of pancreatic and periampullary cancer

https://doi.org/10.1111/hpb.12378Get rights and content
Under an Elsevier user license
open archive

Abstract

Background

After surgical resection of pancreatic adenocarcinoma, most patients will develop recurrence within 2 years. Intense followup is often recommended; however, its impact on survival is unknown. Patient and clinician attitudes towards followup were qualitatively assessed along with the perceived benefits and challenges.

Methods

A semistructured interview guide was developed. Purposive sampling identified patients who were in active surveillance or had developed recurrence. Clinicians involved in patient care were also interviewed. Interviews were conducted until saturation was reached and themes were derived using standard qualitative methods.

Results

A total of 15 patients and seven clinicians were interviewed. Patient themes included a limited understanding of disease prognosis, a desire for reassurance, a desire to know if and when recurrence occurred and minimal difficulties with followup. Clinician themes included expectation that patients are aware of the recurrence risk, a desire to provide reassurance, support for intense followup and perceived patient challenges in followup. Overall, the dominant theme was one of disconnect between patients and clinicians in the understanding of the disease and its prognosis.

Discussion

Patients have an intense need for reassurance and obtain this through followup appointments with their oncologists. Consequently, they express few difficulties with the process. Clinicians recognize this desire for reassurance. Patients' understanding and expectations contrast starkly with clinicians' perspectives regarding prognosis.

Cited by (0)

Portions of this work were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCOGI), 16–18 January 2013, San Francisco, California and the Society of Surgical Oncology Annual Cancer Symposium 12–15 March 2013, Phoenix, Arizona.

*

Cofirst authors.